The isolated rat portal vein as a model for studying beta-adrenoreceptor agonists and antagonists. 1988

K Vidal-Beretervide, and L Castañeda
Department of Pharmacology, School of Medicine, Universidad Centro-Occidental Lisandro Alvarado, Barquisimeto, Venezuela.

1. The isolated rat portal vein was employed for essaying beta-agonists and beta-antagonists. beta-agonists elicit a log-dose dependent reduction of force of the spontaneous, rhythmic, myogenic contractions of the vein. The ID50 dose for isoprenaline was 8.40 +/- 0.04 SEM (negative log. of the molar concentration). Isoprenaline was the most potent of the beta-agonists. If given the value 100, then fenoterol is 75; salbutamol 10; terbutaline 6.75 and during alpha-blockade, adrenaline 28.80 and noradrenaline 0.27. The ratio of potency is thus ISOP greater than FENOT greater than ADR greater than SALB greater than TERB greater than NOR. This suggests that the predominant beta-receptors are beta 2. 2. The duration of effects was shortest for isoprenaline and largest for fenoterol and terbutaline. 3. With the highly potent, specific, competitive beta 2-blocker ICI 118551, a pA2 against isoprenaline of 9.30 (+/- SEM 0.03; C.L. 95% 9.22-9.38) was found. The pA2 against fenoterol, terbutaline, adrenaline and noradrenaline were included in these confidence-limits. With propranolol, a pA2 against isoprenaline of 8.82 (+/- SEM 0.02) was obtained. 4. The high pA2 found against non-selective (isoprenaline, adrenaline) and selective (fenoterol, terbutaline) beta 2-agonists is, as said, practically the same. This, together with the potency ratio ISOP greater than ADR greater than NOR, markedly suggest that the population of beta-receptors in the smooth muscle of the rat portal vein is homogeneously beta 2. 5. The method is very useful to essay beta-agonists and beta-antagonists. As straight regression lines with very high correlation coefficients are obtained, the potency and efficacy of agonists may be relatively easily obtained.

UI MeSH Term Description Entries
D008297 Male Males
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D011169 Portal Vein A short thick vein formed by union of the superior mesenteric vein and the splenic vein. Portal Veins,Vein, Portal,Veins, Portal
D011919 Rats, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations or by parent x offspring matings carried out with certain restrictions. This also includes animals with a long history of closed colony breeding. August Rats,Inbred Rat Strains,Inbred Strain of Rat,Inbred Strain of Rats,Inbred Strains of Rats,Rat, Inbred Strain,August Rat,Inbred Rat Strain,Inbred Strain Rat,Inbred Strain Rats,Inbred Strains Rat,Inbred Strains Rats,Rat Inbred Strain,Rat Inbred Strains,Rat Strain, Inbred,Rat Strains, Inbred,Rat, August,Rat, Inbred Strains,Rats Inbred Strain,Rats Inbred Strains,Rats, August,Rats, Inbred Strain,Strain Rat, Inbred,Strain Rats, Inbred,Strain, Inbred Rat,Strains, Inbred Rat
D011943 Receptors, Adrenergic, beta One of two major pharmacologically defined classes of adrenergic receptors. The beta adrenergic receptors play an important role in regulating CARDIAC MUSCLE contraction, SMOOTH MUSCLE relaxation, and GLYCOGENOLYSIS. Adrenergic beta-Receptor,Adrenergic beta-Receptors,Receptors, beta-Adrenergic,beta Adrenergic Receptor,beta-Adrenergic Receptor,beta-Adrenergic Receptors,Receptor, Adrenergic, beta,Adrenergic Receptor, beta,Adrenergic beta Receptor,Adrenergic beta Receptors,Receptor, beta Adrenergic,Receptor, beta-Adrenergic,Receptors, beta Adrenergic,beta Adrenergic Receptors,beta-Receptor, Adrenergic,beta-Receptors, Adrenergic
D000318 Adrenergic beta-Agonists Drugs that selectively bind to and activate beta-adrenergic receptors. Adrenergic beta-Receptor Agonists,beta-Adrenergic Agonists,beta-Adrenergic Receptor Agonists,Adrenergic beta-Agonist,Adrenergic beta-Receptor Agonist,Betamimetics,Receptor Agonists, beta-Adrenergic,Receptors Agonists, Adrenergic beta,beta-Adrenergic Agonist,beta-Adrenergic Receptor Agonist,Adrenergic beta Agonist,Adrenergic beta Agonists,Adrenergic beta Receptor Agonist,Adrenergic beta Receptor Agonists,Agonist, Adrenergic beta-Receptor,Agonist, beta-Adrenergic,Agonist, beta-Adrenergic Receptor,Agonists, Adrenergic beta-Receptor,Agonists, beta-Adrenergic,Agonists, beta-Adrenergic Receptor,Receptor Agonist, beta-Adrenergic,Receptor Agonists, beta Adrenergic,beta Adrenergic Agonist,beta Adrenergic Agonists,beta Adrenergic Receptor Agonist,beta Adrenergic Receptor Agonists,beta-Agonist, Adrenergic,beta-Agonists, Adrenergic,beta-Receptor Agonist, Adrenergic,beta-Receptor Agonists, Adrenergic
D000319 Adrenergic beta-Antagonists Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. Adrenergic beta-Antagonist,Adrenergic beta-Receptor Blockader,Adrenergic beta-Receptor Blockaders,beta-Adrenergic Antagonist,beta-Adrenergic Blocker,beta-Adrenergic Blocking Agent,beta-Adrenergic Blocking Agents,beta-Adrenergic Receptor Blockader,beta-Adrenergic Receptor Blockaders,beta-Adrenoceptor Antagonist,beta-Blockers, Adrenergic,beta-Adrenergic Antagonists,beta-Adrenergic Blockers,beta-Adrenoceptor Antagonists,Adrenergic beta Antagonist,Adrenergic beta Antagonists,Adrenergic beta Receptor Blockader,Adrenergic beta Receptor Blockaders,Adrenergic beta-Blockers,Agent, beta-Adrenergic Blocking,Agents, beta-Adrenergic Blocking,Antagonist, beta-Adrenergic,Antagonist, beta-Adrenoceptor,Antagonists, beta-Adrenergic,Antagonists, beta-Adrenoceptor,Blockader, Adrenergic beta-Receptor,Blockader, beta-Adrenergic Receptor,Blockaders, Adrenergic beta-Receptor,Blockaders, beta-Adrenergic Receptor,Blocker, beta-Adrenergic,Blockers, beta-Adrenergic,Blocking Agent, beta-Adrenergic,Blocking Agents, beta-Adrenergic,Receptor Blockader, beta-Adrenergic,Receptor Blockaders, beta-Adrenergic,beta Adrenergic Antagonist,beta Adrenergic Antagonists,beta Adrenergic Blocker,beta Adrenergic Blockers,beta Adrenergic Blocking Agent,beta Adrenergic Blocking Agents,beta Adrenergic Receptor Blockader,beta Adrenergic Receptor Blockaders,beta Adrenoceptor Antagonist,beta Adrenoceptor Antagonists,beta Blockers, Adrenergic,beta-Antagonist, Adrenergic,beta-Antagonists, Adrenergic,beta-Receptor Blockader, Adrenergic,beta-Receptor Blockaders, Adrenergic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014661 Vasoconstriction The physiological narrowing of BLOOD VESSELS by contraction of the VASCULAR SMOOTH MUSCLE. Vasoconstrictions
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus

Related Publications

K Vidal-Beretervide, and L Castañeda
September 1982, Journal of autonomic pharmacology,
K Vidal-Beretervide, and L Castañeda
March 1984, Journal of autonomic pharmacology,
K Vidal-Beretervide, and L Castañeda
October 1971, European journal of pharmacology,
K Vidal-Beretervide, and L Castañeda
June 1993, Alimentary pharmacology & therapeutics,
K Vidal-Beretervide, and L Castañeda
October 1982, Lancet (London, England),
K Vidal-Beretervide, and L Castañeda
January 1988, Fundamental & clinical pharmacology,
K Vidal-Beretervide, and L Castañeda
January 2002, Journal of gastroenterology,
K Vidal-Beretervide, and L Castañeda
January 1981, Investigative ophthalmology & visual science,
K Vidal-Beretervide, and L Castañeda
October 1979, Journal of neurology, neurosurgery, and psychiatry,
K Vidal-Beretervide, and L Castañeda
November 1983, Lancet (London, England),
Copied contents to your clipboard!